GENE EXPRESSION OF INTEGRIN RECEPTORS AND THEIR LIGANDS IN PAPILLARY THYROID CARCINOMA WITH DIFFERENT BRAF V600E MUTATION STATUS

DOI: https://doi.org/None

Mostovich L.A., Logacheva G.P., Svyatchenko S.V., Shevchenko S.P., Gulyaeva L.F.

Introduction. Papillary thyroid cancer (PTC) is the most common malignancy of the endocrine system. As the most frequent genetic alteration BRAF V600E mutation in PTC leads to changes in the activity of intracellular signaling pathways. As a result, expression levels of cell membrane integrin receptors and their ligands-extracellular matrix proteins are modified. Such changes promote migration, invasion and metastasis of tumor cells. The aim of the study was to evaluate the gene expression profile of integrins ITGA3, ITGAV, ITGA6, ITGA9, ITGB1 and their ligands OPNa, OPNb, TSP1 in papillary carcinomas with different BRAF V600E mutation status. Methods. To evaluate expression levels of investigated genes intraoperative tissue samples of the thyroid gland from 41 PTC patients (n=26), diffuse nodular nontoxic goiter (n=10) and follicular adenoma (n=5) were investigated by real time RT-PCR, the presence of mutation was determined with the use of allele-specific amplification.Results. An increase of the gene expression level of ITGA3, ITGAV, ITGB1, OPNb and TSP1 was identified in PTC tissue, and the gene expression level of OPNb and TSP1 in tissue samples of regional metastases was found to be over than in compared conventionally normal tissue. In samples with a widespread process (T3, T4), expression levels of ITGA3, ITGA6 and ITGA9 were higher if compared to samples T1. Expression levels of ITGA 3and ITGAV in PTC samples BRAF V600E+ were over BRAF V600E- samples. Conclusion. Integrins and their ligands OPN and TSP1 can be considered as potential markers in the determination of the prognosis of PTC.
Keywords: 
papillary thyroid cancer, BRAF V600E mutation, integrins, osteopontin, thrombospondin-1
Список литературы: 
  1. Tuttle R.M., Ball D.W., Byrd D., Dilawari R.A., Doherty G.M., Duh Q.Y., Ehya H., Farrar W.B., Haddad R.I., Kandeel F., Kloos R.T., Kopp P., Lamonica D.M., Loree D.R., Lydiatt W.M., McCaffrey J.C., Olson J.A. JrParks L., Ridge J.A., Shah J.P., Sherman S.I., Sturgeon C., Waguespack S.G., Wang T.N., Wirth L.J. Thyroidcarcinoma. J. Natl. Compr. Canc. Netw. 2010; 8: 1228–74.
  2. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat. Rev. Cancer. 2013; 13 (3): 184–99.
  3. Kaprin A.D., Starinskiy A.D., Petrova, G.V. Zlokachestvennye novoobrazovaniya v Rossii v 2012 godu (zabolevaemost` i smertnost`). M.: MNIOI im. P.A.Gercena, 2013; 231. [Kaprin A.D., Starinskij A.D., Petrova, G.V. Malignancies in Russia in 2012 (morbidity and mortality). M.: MNIOI im. P.A. Gercena, 2013; 231 (in Russian)]
  4. Romanchishen A.F., Romanchishen F.A., Vabalayte K.V. Hirurgicheskaya profilaktika povrezhdeniy vozvratnyh gortannyh nervov i okoloshhitovidnyh zhelez. Onkohirurgiya. 2013; 2: 52–6. [Romanchishen A.F., Romanchishen F.A., Vabalajte K.V. Surgical prevention of recurrent laryngeal nerves and parathyroid glands injuries. 2013; 2: 52–6 (in Russian)]
  5. Bommarito A.1., Richiusa P., Carissimi E., Pizzolanti G., Rodolico V., Zito, G., Criscimanna A., Di Blasi F., Pitrone M., Zerilli M., Amato M.C., Spinelli G., Carina V., Modica G., Latteri M.A., Galluzzo A., Giordano C. BRAF V600E mutation, TIMP-1 upregulation, and NF-κB activation: closing the loop on the papillary thyroid cancer trilogy. Endocr. Relat. Cancer. 2011; 18 (6): 669–85.
  6. Nikiforov Y.E. Thyroid Carcinoma: Molecular Pathways and Therapeutic Targets. Mod. Pathol. 2008; 2: 37–43.
  7. Nucera C.1., Lawler J., Hodin R., Parangi S. The BRAFV600E mutation: what is it really orchestrating in thyroid cancer? Oncotarget. 2010; 1: 751–6.
  8. Schwartz M.A., Schaller M.D., Ginsberg M.H. Integrins emerging paradigms of signal-transduction. Annu. Rev. Cell. Dev. Biol. 1995; 11: 549–99.
  9. Pieter H.A., Mutrie J.C., Tuck A.B., Ann F. Pre- and post-translational regulation of osteopontin in cancer. J Cell Commun Signal. 2011; 5 (2): 111–22.
  10. Kazerounian S., Yee K.O., Lawler J. Thrombospondins in cancer. Cell. Mol. Life Sci. 2008; 65 (5): 700–12.
  11. Liersch L., Shin J.W., Bayer M., Schwöppe1 C., Schliemann C., Berdel W.E., Mesters R., Detmar M. Analysis of a novel highly metastatic melanoma cell line identifies osteopontin as a new lymphangiogenic factor. International J. Of Oncology. 2012; 41: 1455–63.
  12. Ranjbaril N., Almasi1 S., Mohammadias J. BRAF Mutations in Iranian patients with papillary thyroid carcinoma. Asian Pacific J. Cancer Perv. 2013; 14 (4): 2521–3.
  13. Kim K.H., Kang D.W., Kim S.H., Seong I.O., Kang D.Y. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J. 2004; 45: 818–21.
  14. Desgrosellier J.S., Cheresh D.A. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer. 2010; 10 (1): 9–22.
  15. Shirakihara T., Kawasaki T., Fukagawa A., Semba K., Sakai R., Miyazono K., Miyazawa K., Saitoh M. Identification of integrin α3 as a molecular marker of cells undergoing epithelial-mesenchymal transition and of cancer cells with aggressive phenotypes. Cancer Sci. 2013; 104 (9): 1189–97.
  16. Hou P., Liu D., Shan Y., Hu S., Studeman K., Condouris S., Wang Y., Trink A., El-Naggar A.K., Tallini G., Vasko V., Xing M. Genetic alterations and their relationship in the phosphatidylinositol-3-kinase/Akt pathway in thyroid cancer. Clin. Cancer Res. 2007; 13 (4): 1161–70.